| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | ||||||
|
25.03.2025 15:35:22
|
Resolutions of the Combined Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A.
|
Sartorius Stedim Biotech SA
/ Key word(s): AGM/EGM
Aubagne, France | March 25, 2025
Resolutions of the Combined Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A. At today’s combined Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A., shareholders granted discharge to all Directors by a large majority. The shareholders elected Cécile Dussart and Christopher Nowers as new Board Members. To ensure staggering of office terms, both were appointed for three years while Joachim Kreuzburg was reappointed for two years and René Fáber, Pascale Boissel and Lothar Kappich for four years. Henri Riey, who served on the Board since 2007, decided not to seek re-election. The Board sincerely thanked him for his valuable contributions and expertise over nearly two decades. Effective March 25, 2025, the Board of Directors of Sartorius Stedim Biotech S.A. is composed of: Joachim Kreuzburg (Chairman), René Fáber (CEO), Pascale Boissel, Susan Dexter, Cécile Dussart, Romaine Fernandes (Director Representing Employees), Anne-Marie Graffin (Lead Independent Director), Lothar Kappich, and Christopher Nowers. The shareholders also approved all other resolutions by a large majority, including the proposal to pay a dividend of 0.69 euros per share for fiscal 2024. The total payout will be 67.1 million euros. The dividend will be paid as from April 4, 2025. Further Information Shareholders' Meeting | Sartorius Stedim Biotech S.A. Company images CVs and images of the Directors Financial calendar April 16, 2025 Publication of the first quarter results January to March 2025 July 22, 2025 Publication of the half-year results January to June 2025 October 16, 2025 Publication of the nine-month results January to September 2025 A profile of Sartorius Stedim Biotech Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications, such as cell and gene therapies, safely, rapidly, and sustainably. The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales entities in Europe, North America, and Asia. Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies. In 2024, the company generated sales revenue of around 2.8 billion euros. Currently, more than 9,900 employees are working for customers around the globe. Visit our Newsroom and follow us on LinkedIn. Contact Leona Malorny Head of External Communications +49 551 308 4067 leona.malorny@sartorius.com Attachment File: Sartorius Stedim Biotech S.A._Media Release_Resolutions of the Combined Annual Shareholders’ Meeting
Dissemination of a Financial Wire News, transmitted by EQS Group. |
| Language: | English |
| Issuer: | Sartorius Stedim Biotech SA |
| Avenue de Jouques | |
| 13781 Aubagne | |
| France | |
| Phone: | +33 44 284 5600 |
| E-mail: | sartorius.presse@sartorius.com |
| Internet: | www.sartorius.com |
| ISIN: | FR0013154002 |
| EQS News ID: | 2105416 |
| End of Announcement - EQS News Service | |
|
|
2105416 25-March-2025 CET/CEST
Nachrichten zu Sartorius Stedim Biotech
|
01.04.25 |
Erste Schätzungen: Sartorius Stedim Biotech stellt Ergebnisse des abgelaufenen Quartals vor (finanzen.net) | |
|
25.03.25 |
Resolutions of the Combined Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A. (EQS Group) | |
|
17.02.25 |
Sartorius Stedim Biotech releases Universal Registration Document 2024 (EQS Group) | |
|
07.02.25 |
Board of Directors of Sartorius Stedim Biotech resolves to propose dividend of 0.69 euros per share to Annual Shareholders’ Meeting (EQS Group) | |
|
31.01.25 |
Sartorius Stedim Biotech-Aktie: Was Analysten von Sartorius Stedim Biotech erwarten (finanzen.net) | |
|
28.01.25 |
Sartorius Stedim Biotech publishes preliminary, unaudited results for fiscal 2024 (EQS Group) | |
|
27.01.25 |
Ausblick: Sartorius Stedim Biotech vermeldet Zahlen zum jüngsten Quartal (finanzen.net) | |
|
13.01.25 |
Erste Schätzungen: Sartorius Stedim Biotech präsentiert Quartalsergebnisse (finanzen.net) |
Analysen zu Sartorius Stedim Biotech
| 21.02.25 | Sartorius Stedim Biotech Outperform | RBC Capital Markets | |
| 30.01.25 | Sartorius Stedim Biotech Buy | Goldman Sachs Group Inc. | |
| 30.01.25 | Sartorius Stedim Biotech Buy | Jefferies & Company Inc. | |
| 29.01.25 | Sartorius Stedim Biotech Overweight | JP Morgan Chase & Co. | |
| 29.01.25 | Sartorius Stedim Biotech Neutral | UBS AG |
Investieren in Rüstungsaktien – Wall Street Live mit Tim Schäfer
Tim Schäfer analysiert im Gespräch mit David Kunz (COO der BX Swiss) die spannendsten Defense-Aktien aus Europa und den USA. Sind Rheinmetall, Palantir oder Lockheed Martin noch kaufenswert – oder schon überbewertet?
Wir sprechen über die Rolle von Trumps NATO-Druck, die massive Aufrüstung in Europa und warum gerade europäische Rüstungsaktien boomen.
✅ Top-Performer 2024
✅ Value- und Dividenden-Checks
✅ Geheimtipps wie BAE Systems, Thales & Co.
✅ Palantir als digitaler Profiteur
In unserem zweiwöchigen Format „Wall Street Live“ mit Tim Schäfer behandeln wir Topaktuelle Themen des Marktgeschehens.
🛑 Wichtig: Das Thema Rüstung ist gesellschaftlich wie ethisch komplex – in diesem Video beleuchten wir vor allem die börsentechnische Entwicklung und die wirtschaftlichen Auswirkungen globaler Ereignisse.
👉🏽 https://bxplus.ch/wall-street-live-mit-tim-schaefer/
Inside Trading & Investment
Mini-Futures auf SMI
Aktien in diesem Artikel
| Sartorius Stedim Biotech | 163.80 | -4.77% |
|
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
Globaler Handelskrieg: SMI und DAX mit massivem Kursrutsch ins Wochenende -- US-Börsen rutschen letztlich ab -- Nikkei schliesst tiefrotDer heimische und deutsche Aktienmarkt verzeichnete vor dem Wochenende drastische Verluste. Auch an den US-Börsen ging es tief abwärts. Die japanische Börse verbuchte am Freitag deutliche Abschläge.
finanzen.net News
| Datum | Titel |
|---|---|
|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |